[Propanc Secures $100 Million Financing for Digital Asset Investment and Cancer Therapy Development] Australian biotechnology company Propanc Biopharma (NASDAQ: PPCB) announced that it has secured up to $100 million in financing from Hexstone Capital. Hexstone Capital is a family office specializing in digital assets such as Bitcoin, Ethereum, Solana, and Dogecoin. The financing was completed through a private placement of convertible preferred shares, including an initial investment of $1 million and up to $99 million in follow-up funding over the next year. The funds will be used to build Propanc's digital asset portfolio and accelerate the development of its cancer therapy PRP, with the goal of initiating first human trials in 2026. The company did not disclose the specific digital assets it plans to acquire.